Alejandro
Martín García Sancho
Profesor Asociado CC. Salud
![Foto de Alejandro](/img/uploaded/7995d893f771731596c395e1ae877d0d.jpg)
![Foto de Hospital Universitari Germans Trias i Pujol](/img/noimage_org.png)
Hospital Universitari Germans Trias i Pujol
Barcelona, EspañaPublications en collaboration avec des chercheurs de Hospital Universitari Germans Trias i Pujol (13)
2023
-
Lenalidomide in combination with R-ESHAP in patients with relapsed or refractory diffuse large B-cell lymphoma: A phase 2 study from GELTAMO
British Journal of Haematology, Vol. 203, Núm. 2, pp. 202-211
2022
2021
-
Allogeneic stem cell transplantation as a curative option in relapse/refractory diffuse large B cell lymphoma: Spanish multicenter GETH/GELTAMO study
Bone Marrow Transplantation, Vol. 56, Núm. 8, pp. 1919-1928
-
R-COMP versus R-CHOP as first-line therapy for diffuse large B-cell lymphoma in patients ≥60 years: Results of a randomized phase 2 study from the Spanish GELTAMO group
Cancer Medicine, Vol. 10, Núm. 4, pp. 1314-1326
2020
-
Avadomide monotherapy in relapsed/refractory DLBCL: safety, efficacy, and a predictive gene classifier
Blood, Vol. 135, Núm. 13, pp. 996-1007
-
Diagnostic delay and outcome in immunocompetent patients with primary central nervous system lymphoma in Spain: a multicentric study
Journal of Neuro-Oncology, Vol. 148, Núm. 3, pp. 545-554
-
Evaluation of the MD Anderson tumor score for diffuse large B-cell lymphoma in the rituximab era
European Journal of Haematology, Vol. 104, Núm. 5, pp. 400-408
-
New prognosis score including absolute lymphocyte/monocyte ratio, red blood cell distribution width and beta-2 microglobulin in patients with diffuse large B-cell lymphoma treated with R-CHOP: Spanish Lymphoma Group Experience (GELTAMO)
British Journal of Haematology, Vol. 188, Núm. 6, pp. 888-897
2019
-
Life expectancy of follicular lymphoma patients in complete response at 30 months is similar to that of the Spanish general population
British Journal of Haematology, Vol. 185, Núm. 3, pp. 480-491
-
Response-adapted treatment with rituximab, bendamustine, mitoxantrone, and dexamethasone followed by rituximab maintenance in patients with relapsed or refractory follicular lymphoma after first-line immunochemotherapy: Results of the RBMDGELTAMO08 phase II trial
Cancer Medicine, Vol. 8, Núm. 16, pp. 6955-6966
2018
-
Differential prognostic impact of GELTAMO-IPI in cell of origin subtypes of Diffuse Large B Cell Lymphoma as defined by the Hans algorithm
British Journal of Haematology, Vol. 182, Núm. 4, pp. 534-541
2017
-
Autologous stem cell transplantation (ASCT) in patients with mantle cell lymphoma: a retrospective study of the Spanish lymphoma group (GELTAMO)
Annals of Hematology, Vol. 96, Núm. 8, pp. 1323-1330
-
Validation of the NCCN-IPI for diffuse large B-cell lymphoma (DLBCL): the addition of β2-microglobulin yields a more accurate GELTAMO-IPI
British Journal of Haematology, Vol. 176, Núm. 6, pp. 918-928